Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

SGMO Sangamo Therapeutics Inc

0,5197

0,0173 (3,44%)

Zuletzt aktualisiert: 16:46:03

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Sangamo Therapeutics Charts.

News Sangamo Therapeutics Inc

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Donnerstag 9 Mai 2024 (3 Stunden vor) • Business Wire

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Donnerstag 2 Mai 2024 (7 Tage vor) • Business Wire

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Montag 22 April 2024 (2 Wochen vor) • Business Wire

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Freitag 22 März 2024 (2 Monate vor) • Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Mittwoch 13 März 2024 (2 Monate vor) • Business Wire

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Mittwoch 13 März 2024 (2 Monate vor) • Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Dienstag 12 März 2024 (2 Monate vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 27 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 27 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 27 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 27 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 27 Februar 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Sangamo Therapeutics Inc News-Artikel

Deutsche Telekom

Euro vs Sterling

Deutsche Telekom (QX)

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen